Realcan Pharmaceutical Group Co (SZSE:002589) Interest Expense : ¥-313 Mil (TTM As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Realcan Pharmaceutical Group Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Realcan Pharmaceutical Group Co's interest expense for the three months ended in Sep. 2023 was ¥ -80 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was ¥-313 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Realcan Pharmaceutical Group Co's Operating Income for the three months ended in Sep. 2023 was ¥ 30 Mil. Realcan Pharmaceutical Group Co's Interest Expense for the three months ended in Sep. 2023 was ¥ -80 Mil. Realcan Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Sep. 2023 was 0.37. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Realcan Pharmaceutical Group Co Interest Expense Historical Data

The historical data trend for Realcan Pharmaceutical Group Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Realcan Pharmaceutical Group Co Interest Expense Chart

Realcan Pharmaceutical Group Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-576.25

-737.11

-590.12

-554.42

-407.71

Realcan Pharmaceutical Group Co Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-96.48	-65.65	-122.64	-44.97	-80.15

Realcan Pharmaceutical Group Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-313 Mil.

Realcan Pharmaceutical Group Co (SZSE:002589) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Realcan Pharmaceutical Group Co's Interest Expense for the three months ended in Sep. 2023 was ¥-80 Mil. Its Operating Income for the three months ended in Sep. 2023 was ¥30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was ¥177 Mil.

Realcan Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2023 )	/	Interest Expense (Q: Sep. 2023 )
	=	-1	*	29.773	/	-80.153
	=	0.37

The higher the ratio, the stronger the company's financial strength is.

Realcan Pharmaceutical Group Co (SZSE:002589) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Realcan Pharmaceutical Group Co Ltd (SZSE:002589) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004

Website

http://www.realcan.cn

Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.

Realcan Pharmaceutical Group Co (SZSE:002589) Headlines

No Headlines